{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected for assessing pharmacodynamic parameters.","groups":[{"description":"Part 1A consist of dose escalation of BMS-986466 in combination with adagrasib in KRAS G12C-mutant NSCLC, PDAC, BTC, and CRC.","id":"OG000","title":"Part 1A"},{"description":"Part 1B was planned to evaluate the dose escalation of BMS-986466 in combination with adagrasib plus Cetuximab in KRAS G12C-mutant CRC.","id":"OG001","title":"Part 1B"}],"populationDescription":"All treated participants with available biomarker data. Participants were not enrolled in Part 1a and 1b arm, hence participants analyzed is 0. Prespecified to be collected for Part 1A and 1B only.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 1 Day 1 (Each cycle consist of 28 days)","title":"Part 1a and 1b - Changes From Baseline in Pharmacodynamic Biomarker","type":"SECONDARY"}